Getting a Second Opinion on Lu-177 PSMA Eligibility Before You Commit to Treatment: What to Prepare and How the Expert Review Works

This article is for men with metastatic castration-resistant prostate cancer (mCRPC) who have heard about lutetium Lu-177 vipivotide tetraxetan (brand name Pluvicto) and want to know whether they qualify before starting a treatment plan. It covers what you need to gather, how a specialist review team will assess your case, and what happens if the answer is no.

What Should You Prepare for a Lu-177 PSMA Eligibility Review?

A specialist can usually give you a first assessment within a few days of receiving your records. The more complete your file, the faster and more accurate that review will be. Here is what to gather before you reach out.

1. Your PSMA-PET scan images and the written report. This is the single most important item. Ask your imaging center for the DICOM files (the standard digital format for medical images) on a USB drive or via a secure transfer link. A printed summary alone is not enough. The reviewing physician needs to see the actual scan images to judge the uptake pattern across your lesions.
2. Your full treatment history in order. A clear list of every therapy you have received, with start and stop dates. Include androgen deprivation therapy (ADT), any androgen receptor pathway inhibitors such as abiraterone or enzalutamide, and any taxane-based chemotherapy such as docetaxel or cabazitaxel.
3. Recent blood test results. Ideally from within the last four to six weeks. The reviewer will want your PSA trend, complete blood count, kidney function (creatinine), and liver enzymes.
4. Your pathology report. From your original biopsy or any later tissue samples. This confirms the diagnosis and the tumor grade.
5. Your PSA history over time. A table or graph of PSA values tells the reviewer how quickly your disease is progressing.
6. Any other recent imaging. A CT scan of the chest, abdomen, and pelvis, plus a bone scan or whole-body MRI if you have one. These help the reviewer understand the full extent of your disease beyond what the PSMA-PET shows.
7. A list of current symptoms and medications. Include pain medications, supplements, and any other treatments you are taking.

If you are unsure which blood tests should be in your file before submitting for review, our guide on what blood tests and scans you need before Lu-177 PSMA treatment covers the pre-therapy screening checklist.

Why a Second Opinion on Eligibility Actually Matters

Eligibility for Lu-177 PSMA therapy is not a simple yes or no. Several factors interact, and different specialists may weigh them differently.

The PSMA-PET scan itself requires interpretation. A substudy of the VISION trial published in PMC showed that even trained readers can disagree on whether a specific lesion meets the uptake threshold for eligibility. If your scan was read by a radiologist with less experience in PSMA theranostics, a specialist in nuclear medicine may reach a different conclusion.

Treatment sequencing also matters. The approved label for lutetium Lu-177 vipivotide tetraxetan requires prior treatment with an androgen receptor pathway inhibitor and at least one taxane-based chemotherapy regimen. But real-world cases are rarely that clean. Some patients could not tolerate chemotherapy, or received treatments in a different order. A specialist reviewer can assess whether you fit the standard criteria or whether an alternative access pathway (such as a clinical trial or a compassionate use program) may apply to your situation.

Third, some patients are told they are not eligible by one team and later found to be eligible by another. If your oncologist ruled out Lu-177 PSMA without referring you to a nuclear medicine or theranostics team, a formal second opinion is worth pursuing before you accept that conclusion.

What Is Lu-177 PSMA Therapy?

Lutetium Lu-177 vipivotide tetraxetan is a radioligand therapy. It combines a targeting molecule that seeks out the PSMA protein (prostate-specific membrane antigen) on prostate cancer cells with a radioactive payload that delivers localized radiation directly to those cells. PSMA is overexpressed on most prostate cancer cells, which makes this approach possible. Because the radiation travels only a short distance in tissue, healthy surrounding cells receive much less exposure than with conventional external radiation.

The US Food and Drug Administration approved lutetium Lu-177 vipivotide tetraxetan in March 2022 for adults with PSMA-positive mCRPC who had received prior androgen receptor pathway inhibition and taxane-based chemotherapy. The approval was based on the VISION trial, which found a median overall survival of 15.3 months in the treatment group versus 11.3 months in the control group. The FDA approval summary published in PMC describes this difference as statistically significant and clinically important, with a hazard ratio of 0.62.

For a plain-language explanation of how the therapy works at the cellular level, our article on how Lu-177 PSMA works and what theranostics means for your case explains the mechanism step by step.

How the Expert Eligibility Review Actually Works

Here is what typically happens once you send your records to a nuclear medicine or theranostics team for a second opinion.

Step 1 - Record intake. Your submitted documents are checked for completeness. If something key is missing, the team contacts you to fill the gap. This step usually takes 24 to 48 hours.

Step 2 - Scan review by a nuclear medicine specialist. Your PSMA-PET images are reviewed by a physician trained in theranostics. They look at the PSMA uptake pattern across your lesions, whether uptake is higher than the liver background (the standard visual threshold from the VISION trial), and whether any lesions show low or absent PSMA expression. The Mayo Clinic explains that the PSMA PET scan is the primary tool for confirming whether a patient's cancer expresses the target protein at a level that makes radioligand therapy a viable option.

Step 3 - Clinical record review. A medical oncologist or theranostics specialist reviews your treatment history and lab results. They check whether you meet the prior treatment requirements, assess your organ function, and flag any factors that might affect safety or response (such as low platelet counts, impaired kidney function, or extensive liver involvement).

Step 4 - Case discussion. At most specialist centers, the findings from steps 2 and 3 are discussed between the nuclear medicine physician and an oncologist, or at a multidisciplinary team meeting. This is where a recommendation is formed.

Step 5 - Written summary to you. You receive a written summary stating whether you appear to be a candidate, what additional tests would be needed to confirm eligibility, and what next steps are recommended. If Lu-177 PSMA is not currently indicated, the summary should address what alternatives may exist for your specific profile.

If you are based outside a country where Lu-177 PSMA therapy is readily available, you can request a second opinion through Art of Healing Cancer on whether Lu-177 is right for you and what alternatives exist. The team can review your PSMA-PET images and clinical records remotely, without requiring travel at this stage.

What the Reviewer Will Check Against the Eligibility Criteria

The VISION trial established the framework that most centers and regulatory bodies now use to assess eligibility. The core criteria include the following.

PSMA-PET positivity. The VISION trial required at least one PSMA-positive metastasis, defined as uptake greater than the liver background on a 68Ga-PSMA-11 PET/CT scan, with no measurable lesion showing uptake at or below liver level. The VISION trial publication in PMC describes this imaging threshold in detail. If your scan used a different tracer, the reviewer may request a new scan with the standard 68Ga-PSMA-11 or 18F-DCFPyL tracer before giving you a firm answer.

Prior treatment. The standard label requires at least one androgen receptor pathway inhibitor and at least one taxane-based chemotherapy regimen. Patients who were unable to receive chemotherapy for medical reasons may qualify through an alternative pathway, which a specialist can advise on individually.

Performance status. Most centers use the ECOG scale (a scoring system that measures how well you are able to manage ordinary daily activities). Scores of 0 to 2, meaning you can care for yourself even if you cannot do strenuous work, are generally within the standard eligibility window. ECOG 3 or 4 typically places patients outside that window, though each case is assessed on its own facts.

Organ function. Kidney function, blood counts, and liver enzymes all feed into the safety assessment. These values can change over time, so the reviewer needs results from the past four to six weeks. Older results may not reflect where you are today.

Castrate testosterone level. You must have a confirmed castrate testosterone level (below 50 ng/dL) maintained through ongoing ADT or after surgical castration.

Disease extent and distribution. Patients with very extensive liver involvement or very large soft-tissue disease may not respond as well. The reviewer will note this alongside the scan findings to give you an honest picture. If you have already been formally denied therapy and want to understand the specific reasons and what comes next, our article on what to do if you have been denied Lu-177 PSMA therapy covers the appeals and alternatives process.

What Happens If the Second Opinion Says You Are Not Eligible?

A second opinion that confirms ineligibility is still useful. It tells you exactly where the gap is. Sometimes that gap is something that may change (for example, a blood count that improves after a treatment pause, or a clinical trial that studies Lu-177 PSMA in patients who do not yet meet the standard label criteria). Other times it points you toward a different therapy line entirely.

A thorough reviewing team should not simply say no and leave it there. They should explain exactly why the therapy is not suitable right now and outline what your realistic next options are. Two questions are worth asking directly: what would need to change for Lu-177 PSMA to become an option, and what are the evidence-based alternatives for someone with your exact profile. Those two questions alone can open productive conversations with your broader oncology team and help you move forward rather than staying in limbo.

During the time between submitting your records and receiving a verdict, the anxiety and disrupted sleep are real. If you are looking for immediate support, you might explore evidence-informed over-the-counter options for managing stress and sleep during this time.

When to Talk to Your Doctor

Seek a specialist second opinion without delay if your PSA is rising despite your current therapy, if your most recent scans show new or growing lesions, or if your oncologist has not discussed Lu-177 PSMA as a potential next step and has not referred you to a nuclear medicine team. Acting sooner preserves more options. A second opinion does not mean abandoning your current care team - it means making sure you have the complete picture before committing to a path.

To submit your records for a remote eligibility review, use the Lutetium Therapy contact form. If Lu-177 PSMA turns out not to be the right fit for your case, the team can advise on alternative options suited to your specific situation.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.